PSMA/MRI-guided prostate SABR with focal boost showed strong two-year imaging response
In ARGOS-CLIMBER, PSMA/MRI-guided five-fraction pelvic SABR produced a 67% PET complete response rate at two years with limited late GU toxicity.
In ARGOS-CLIMBER, PSMA/MRI-guided five-fraction pelvic SABR produced a 67% PET complete response rate at two years with limited late GU toxicity.
HYPO-RT-PC showed persistently poor agreement between patient- and clinician-reported toxicity, particularly for urinary and bowel symptoms.
Failure-free survival was 96.6% at 12 months, while grade 3 GU toxicity increased to 12.5% by one year.
Patient-specific feasibility guidance improved target homogeneity and reduced rectal low-dose exposure after automated RapidPlan optimization.
Double-arc VMAT was slightly more robust, but single-arc planning achieved clinically comparable dosimetry with simulated bilateral hip prostheses.
Ten-year biochemical control was 64.7% after salvage proton therapy, with 3.2% late grade 3 genitourinary toxicity.
Late urinary worsening occurred in 80% after >40 Gy prostate SBRT versus 68% after ≤40 Gy, while bowel outcomes remained similar.
Daily adaptive salvage radiotherapy produced 6% new grade ≥2 urinary toxicity at 12 months in a prospective 51-patient cohort.
Four-year biochemical control was similar with 65 Gy in 26 fractions and 66 Gy in 33 fractions, while gastrointestinal toxicity was higher.
AI-generated synthetic CT achieved 99.8% gamma agreement with conventional CT while automated pelvic contours remained within expert interobserver variability.
Across five phase III trials, whole-pelvic radiotherapy did not improve overall survival, and progression benefits disappeared when POP-RT was excluded.
Five-year PSA progression-free survival was 24.8% after two-fraction salvage HDR brachytherapy without androgen deprivation, despite low severe toxicity.
Most multicenter salvage prostate radiotherapy plans met SPPORT and RADICALS-HD organ constraints, with smaller bladder volumes linked to more violations.
Carbon ions prolonged tumor-cell damage while chronic hypoxia supported late proliferative and macrophage rebound in rat prostate tumors.
Combining ISUP grade with 3–6-month PSA-density kinetics separated seven-year biochemical control at 93.5% versus 53.4% after SABR without ADT.